1-(5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)-2-methylpropan-2-ol | 1270029-94-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡唑类
• 英文名称: 1-(5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)-2-methylpropan-2-ol
• 英文别名: 1-(5,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5-ium-2-yl)-2-methylpropan-2-ol；1-(5,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-2-yl)-2-methyl-propan-2-ol；1-(5,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-2-yl)-2-methylpropan-2-ol
• CAS: 1270029-94-1
• 化学式: C₉H₁₅N₃O
• 分子量: 181.238
• InChiKey: XSXPBVAAHWMVCS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  50.1
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-溴-4-氯-2-氟苯 、 1-(5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)-2-methylpropan-2-ol 在 氯(2-二环己基膦基-2',6'-二异丙氧基-1,1'-联苯)[2-(2-氨基乙基苯基)]钯(II) 、 三氟乙酸 、 sodium t-butanolate 作用下， 以 四氢呋喃 、 甲基叔丁基醚 为溶剂， 反应 17.0h， 生成 1-[5-(4-chloro-2-fluorophenyl)-4,6-dihydropyrrolo[3,4-c]pyrazol-2-yl]-2-methylpropan-2-ol
  参考文献：
  名称：

  NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[E,2-B]FURAN DERIVATIVES

  摘要：

  结构式（I）的新化合物是AMP-蛋白激酶的激活剂，可能在治疗、预防和抑制由AMPK激活的蛋白激酶介导的疾病中有用。本发明的化合物可能在治疗2型糖尿病、高血糖、代谢综合征、肥胖、高胆固醇血症和高血压方面有用。

  公开号：

  US20150284411A1

文献信息

• [EN] SUBSTITUTED SEVEN-MEMBERED HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES SUBSTITUÉS À SEPT CHAÎNONS EN TANT QU'INHIBITEURS DE LA DIPEPTIDYL-PEPTIDASE IV POUR LE TRAITEMENT DU DIABÈTE
  申请人：MERCK SHARP & DOHME

  公开号：WO2011146358A1

  公开（公告）日：2011-11-24

  The present invention is directed to novel amino-substituted seven-membered heterocyclic compounds of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及结构式（I）的新型氨基取代的七元杂环化合物，这些化合物是二肽基肽酶-IV酶的抑制剂，并且在治疗或预防二肽基肽酶-IV酶参与的疾病中有用，如糖尿病，特别是2型糖尿病。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗二肽基肽酶-IV酶参与的这类疾病中使用这些化合物和组合物。
• [EN] SUBSTITUTED AMINOTETRAHYDROTHIOPYRANS AND DERIVATIVES THEREOF AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES<br/>[FR] AMINOTÉTRAHYDROTHIOPYRANES SUBSTITUÉS ET DÉRIVÉS DE CEUX-CI UTILISÉS EN TANT QU'INHIBITEURS DE LA DIPEPTIDYLPEPTIDASE-IV DANS LE CADRE DU TRAITEMENT DU DIABÈTE
  申请人：MERCK SHARP & DOHME

  公开号：WO2011103256A1

  公开（公告）日：2011-08-25

  The present invention is directed to novel substituted aminotetrahydrothiopyrans and derivatives thereof of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及一种新型的取代氨基四氢硫代吡喃及其衍生物，其化学结构式为(I)，这些化合物是二肽基肽酶-IV酶的抑制剂，对于治疗或预防二肽基肽酶-IV酶参与的疾病非常有用，例如糖尿病，特别是2型糖尿病。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗二肽基肽酶-IV酶参与的这类疾病中使用这些化合物和组合物。
• [EN] AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES<br/>[FR] AMINOTÉTRAHYDROPANES UTILISÉS COMME INHIBITEURS DE LA DIPEPTYL PEPTIDASE-IV POUR TRAITER OU PRÉVENIR LE DIABÈTE
  申请人：MERCK SHARP & DOHME

  公开号：WO2011028455A1

  公开（公告）日：2011-03-10

  The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及结构式I的新型取代氨基四氢吡喃衍生物，它们是二肽基肽酶-IV酶的抑制剂，并且在治疗或预防二肽基肽酶-IV酶参与的疾病，如糖尿病，特别是2型糖尿病方面具有用途。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗二肽基肽酶-IV酶参与的这类疾病中使用这些化合物和组合物。
• [EN] NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS<br/>[FR] NOUVEAUX DÉRIVÉS D'AZABENZIMIDAZOLE CYCLIQUE UTILES EN TANT QU'AGENTS ANTIDIABÉTIQUES
  申请人：MERCK SHARP & DOHME

  公开号：WO2012116145A1

  公开（公告）日：2012-08-30

  Novel compounds of structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.

  结构式（I）的新化合物是AMP-蛋白激酶的激活剂，可用于治疗、预防和抑制由AMPK激活的蛋白激酶介导的疾病。本发明的化合物可用于治疗2型糖尿病、高血糖、代谢综合征、肥胖、高胆固醇血症和高血压。
• [EN] ANTIDIABETIC TRICYCLIC COMPOUNDS<br/>[FR] COMPOSÉS TRICYCLIQUES ANTIDIABÉTIQUES
  申请人：MERCK SHARP & DOHME

  公开号：WO2015073342A1

  公开（公告）日：2015-05-21

  Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

  结构式（I）的新化合物及其药用盐是G蛋白偶联受体40（GPR40）的激动剂，可能对通过G蛋白偶联受体40介导的疾病的治疗、预防和抑制具有用处。本发明的化合物可能对治疗2型糖尿病以及与该疾病常相关的病症，包括肥胖和脂质紊乱，如混合型或糖尿病性脂质代谢异常、高脂血症、高胆固醇血症和高三酸甘油脂血症具有用处。